Anika (NASDAQ: ANIK) lifts margins as 2025 loss narrows sharply
Rhea-AI Filing Summary
Anika Therapeutics reported fourth quarter and full-year 2025 results and outlined leadership transition plans for its General Counsel. Q4 2025 revenue was $30.6 million, essentially flat year over year, with gross margin expanding to 63%. Commercial Channel revenue grew 22% while OEM Channel revenue declined 12%.
For full-year 2025, revenue was $112.8 million, down 6% from 2024, but gross margin improved to 57%. The company generated $11.2 million in operating cash flow and $4.4 million in free cash flow, and reduced its net loss to $10.9 million from $56.4 million in 2024. Adjusted EBITDA was $5.3 million in 2025 versus $15.5 million in 2024.
Anika continued a $15 million Rule 10b5-1 share repurchase program, funding $10.7 million to date and expecting completion in the second quarter of 2026. The company received an FDA response to its Hyalofast PMA in January 2026 and is preparing follow-up submissions, while progressing remaining requirements for the Cingal NDA. Separately, Anika entered a Transition Agreement under which Executive Vice President, General Counsel and Corporate Secretary David Colleran will remain in his role through May 1, 2026, with continued salary, benefits, and equity vesting, and will receive separation benefits pursuant to his Executive Retention Agreement in exchange for a general release of claims.
Positive
- None.
Negative
- None.
Insights
Channel mix shifted toward higher-margin commercial sales, improving profitability despite lower 2025 revenue.
Anika delivered flat Q4 revenue of
The company cut its net loss to
Strategically, management highlighted progress on key pipeline assets, including the Hyalofast PMA and Cingal NDA work, and continued a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On February 26, 2026, Anika Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 26, 2026, the Company and Mr. Colleran entered into a Transitional Services and General Release of Claims Agreement (the “Transition Agreement”). Pursuant to the Transition Agreement, Mr. Colleran will continue to be employed by the Company as its Executive Vice President, General Counsel and Corporate Secretary through May 1, 2026 (the “Anticipated Separation Date”), unless Mr. Colleran resigns or is terminated for Cause (as defined in the Transition Agreement) prior to that date. Until the Anticipated Separation Date, Mr. Colleran will continue to provide his existing services to the Company and such other services as the Chief Executive Officer or the Chief Executive Officer’s designee requests, and will receive his current salary and benefits as a regular employee, except Mr. Colleran will not accrue vacation during such period. The Transition Agreement also provides that, provided Mr. Colleran fully complies with the Transition Agreement, is not terminated for Cause or breach and does not resign, and signs and returns the certificate attached to the Transition Agreement within the 7 days following the Anticipated Separation Date, the Company shall pay Mr. Colleran the consideration provided in Sections 4(b) or 5(a) of his Executive Retention Agreement, dated as of December 12, 2024 (the “ERA”), as applicable in accordance with the payment terms described in the ERA. Mr. Colleran continues to be bound by the terms and conditions of the Confidentiality and Proprietary Rights Agreement. Mr. Colleran’s equity awards granted under the Company’s Omnibus Incentive Plan shall continue to vest during the Transition Period, subject to the applicable equity agreements and the Company’s equity plan. Additionally, in consideration of the separation pay and benefits provided under the ERA, Mr. Colleran has provided the Company, its affiliates and related parties with a general release of claims.
The foregoing description of the Transition Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K, and incorporated by reference herein.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number |
Description | |
| 10.1 | Transitional Services and General Release of Claims Agreement dated as of February 26, 2026, between Anika Therapeutics, Inc. and David Colleran | |
| 10.2 | Executive Retention Agreement, dated December 12, 2024, by and between Anika Therapeutics, Inc. and David Colleran (incorporated by reference to Exhibit 10.13 to the Registrant’s Annual Report on Form 10-K (File No. 001-14027) filed on March 17, 2025) | |
| 99.1 | Press release dated February 26, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Anika Therapeutics, Inc. | ||||||
| Date: February 26, 2026 | By: | /s/ Stephen Griffin | ||||
| Stephen Griffin | ||||||
| President and Chief Executive Officer | ||||||
Exhibit 99.1
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target
Commercial Channel grew 22% and 15% for Q4 and full year, respectively
Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year
FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission
Bedford, Mass., February 26, 2026 — Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early-intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025.
Anika reported fourth quarter revenue of $30.6 million, flat compared to the fourth quarter of 2024. Gross margin expanded to 63%, driven by favorable product mix and operating leverage. Commercial Channel revenue increased 22% year over year driven by timing of 2025 shipments to international customers and growth in the IntegrityTM Implant System, while OEM Channel revenue declined 12%, reflecting anticipated U.S. OA Pain Management pricing dynamics.
For the full year 2025, total revenue was $112.8 million, a decrease of 6% compared to 2024, in line with expectations. Commercial Channel revenue increased 15% year over year, supported by continued Integrity growth and international OA Pain Management performance. OEM Channel revenue declined 17% for the year driven by lower Monovisc® and Orthovisc® pricing in the U.S. The Company delivered 57% gross margin for the year and generated $11.2 million in operating cash flow and $4.4 million in free cash flow.
“We closed 2025 with a strong fourth quarter, with top-line growth led by our Commercial Channel and company-wide results that included expanded gross margin, and positive operating income and free cash flow,” said Steve Griffin, President and Chief Executive Officer of Anika Therapeutics. “Our operating income performance in the fourth quarter and full year underscores the strength of our core OA Pain Management business despite U.S. pricing headwinds in 2025 and establishes a foundation for improved profitability.
2025 was an important year for advancing our product portfolio, highlighted by more than doubling Integrity procedures, the filing of the Hyalofast PMA with the FDA, and continued progress on the remaining filing requirements, the toxicity and bioequivalence studies, for the Cingal® NDA. Cingal and Hyalofast remain core strategic priorities for 2026 as we prepare for future U.S. market launches.
I’m proud to lead this organization as we build upon a strong foundation and deliver results for patients and shareholders. Looking ahead, our priorities are driving revenue and volume growth, including building on the momentum in our Commercial Channel; advancing our R&D pipeline; and improving execution – supported by rigorous expense management and productivity improvements at our manufacturing facility – to enhance profitability.”
Fourth Quarter and Full Year 2025 Business Highlights and Current Business Updates
| • | International OA Pain Management grew 28% and 12% in the fourth quarter and full year, respectively, led by the international sales team’s continued regional expansion and improved market share. |
| • | Integrity continued to demonstrate strong momentum, with procedures increasing for the seventh consecutive quarter and revenue more than doubling in 2025 to $6 million, driven by sustained surgeon adoption in the U.S., new line extensions, and expanding international penetration. |
| • | Hyalofast PMA responses were received from the FDA in January 2026 as expected, and the Company is preparing responses to PMA deficiencies. The FDA review remains in line with the previously provided extended timeline. |
| • | Successfully completed Cingal toxicity studies initiated in 2025; bioequivalence study initiated in December 2025 in preparation for an FDA NDA submission. |
| • | The Company has initiated actions to reduce general and administrative expenses in the first half of 2026, reflecting a more focused cost structure following recent strategic divestitures and supporting continued investment in manufacturing and product development. Following these actions and customary transition periods for affected team members, the Company anticipates approximately $2.5 million in annualized adjusted EBITDA savings and $3.0 million in annualized stock-based compensation savings. |
Fourth Quarter 2025 Continuing Operations Financial Summary
| • | Revenue $30.6 million, flat year over year |
| • | Commercial Channel revenue $13.3 million, up 22% |
| • | OEM Channel revenue $17.3 million, down 12% |
| • | Gross margin 63% |
| • | Operating expenses $18.5 million |
| • | GAAP income from continuing operations $1.8 million, $0.13 per diluted share |
| • | Adjusted net income from continuing operations1 $4.6 million, $0.31 per diluted share |
| • | Adjusted EBITDA1 $4.5 million |
| • | Cash and cash equivalents $57.5 million as of December 31, 2025 |
Full Year 2025 Continuing Operations Financial Summary
| • | Revenue $112.8 million, down 6% year over year |
| • | Commercial Channel revenue $48.4 million, up 15% |
| • | OEM Channel revenue $64.4 million, down 17% |
| • | Gross margin 57% |
| • | Operating expenses $74.9 million |
| • | GAAP loss from continuing operations $(10.0) million, $(0.70) per diluted share |
| • | Adjusted net income from continuing operations1 $1.6 million, $0.11 per diluted share |
| • | Adjusted EBITDA1 $5.3 million |
| 1 | See description of non-GAAP financial information contained in this release. |
Fiscal 2026 Guidance
Anika is providing the following 2026 guidance:
| • | Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year |
| • | Commercial Channel, $53 to $58 million, maintaining up 10% to 20% year over year |
| • | OEM Channel, $61 to $64.5 million, maintaining flat to modestly lower year over year |
| • | Adjusted EBITDA as a percent of revenue to 5% to 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics. |
Company Continues $15 Million 10b5-1 Share Repurchase
In accordance with Anika’s commitment to return capital to shareholders while maintaining the flexibility to execute on strategic growth objectives, the Company is continuing the $15 million 10b5-1 share repurchase which commenced in Q4 2025. Through the end of Q4 2025, the Company funded $5.5 million of this share repurchase commitment. To date, the Company has funded $10.7 million of the commitment, and the program’s completion is expected in the second quarter of 2026.
Conference Call and Webcast Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Thursday, February 26, 2026, at 8:30 am ET. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
Non-GAAP Financial Information1
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Anika strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company’s operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.
Adjusted EBITDA
Adjusted EBITDA is defined by the Company as GAAP net income (loss) from continuing operations excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, and shareholder activism costs.
Adjusted Net Income (Loss) from Continuing Operations and Adjusted EPS from Continuing Operations
Adjusted net income (loss) is defined by the Company as GAAP net income from continuing operations, on a tax effected basis, excluding stock-based compensation. Adjusted diluted EPS from continuing operations is defined by the Company as GAAP diluted EPS from continuing operations excluding stock-based compensation.
A reconciliation of adjusted EBITDA to adjusted net income (loss) from continuing operations to net income (loss) from continuing operations and adjusted diluted EPS from continuing operations to diluted EPS from continuing operations, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.
Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company’s expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including statements in Mr. Griffin’s quote about revenue and volume growth, the Company’s portfolio and improving profitability, statements about the clinical and regulatory pathway with respect to Hyalofast in the U.S., statements about the anticipated regulatory pathway for the NDA filing for Cingal, statements about potential savings associated with the reduction of general and administrative expenses, statements regarding the timing of the share repurchase program, and statements in the sub-headings and the section titled “Fiscal 2026 Guidance” regarding 2026 revenue and adjusted EBITDA. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support, or to timely file domestic and international pre-market approval applications, 510(k) applications, or new drug applications, including the PMA for Hyalofast and the NDA for Cingal; (iii) that the FDA or other regulatory bodies may not approve or clear the Company’s applications, including the Hyalofast PMA because of the failure to achieve the pre-defined primary endpoints or because the FDA may determine that achievement of secondary endpoints and/or post hoc data analyses are not sufficient to support approval; (iii) that such approvals or clearances will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the
Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (x) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC’s website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
| For the Three Months Ended December 31, | For the Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue |
$ | 30,615 | $ | 30,602 | $ | 112,819 | $ | 119,907 | ||||||||
| Cost of Revenue |
11,436 | 13,476 | 49,012 | 43,909 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Gross Profit |
19,179 | 17,126 | 63,807 | 75,998 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Research and development |
6,452 | 6,507 | 25,770 | 25,544 | ||||||||||||
| Selling, general and administrative |
12,081 | 11,324 | 49,088 | 55,555 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
18,533 | 17,831 | 74,858 | 81,099 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
646 | (705 | ) | (11,051 | ) | (5,101 | ) | |||||||||
| Interest and other income (expense), net |
118 | 744 | 1,744 | 2,337 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income (loss) before income taxes |
764 | 39 | (9,307 | ) | (2,764 | ) | ||||||||||
| Provision for income taxes |
(1,037 | ) | 2,525 | 672 | 6,064 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income (loss) from continuing operations |
1,801 | (2,486 | ) | (9,979 | ) | (8,828 | ) | |||||||||
| Loss from discontinued operations, net of tax |
(1,509 | ) | (19,379 | ) | (901 | ) | (47,557 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
$ | 292 | $ | (21,865 | ) | $ | (10,880 | ) | $ | (56,385 | ) | |||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) per share: |
||||||||||||||||
| Basic |
||||||||||||||||
| Continuing Operations |
$ | 0.13 | $ | (0.17 | ) | $ | (0.70 | ) | $ | (0.60 | ) | |||||
| Discontinued Operations |
$ | (0.11 | ) | $ | (1.33 | ) | $ | (0.06 | ) | $ | (3.23 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| $ | 0.02 | $ | (1.50 | ) | $ | (0.76 | ) | $ | (3.83 | ) | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
||||||||||||||||
| Continuing Operations |
$ | 0.12 | $ | (0.17 | ) | $ | (0.70 | ) | $ | (0.60 | ) | |||||
| Discontinued Operations |
$ | (0.10 | ) | $ | (1.33 | ) | $ | (0.06 | ) | $ | (3.23 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| $ | 0.02 | $ | (1.50 | ) | $ | (0.76 | ) | $ | (3.83 | ) | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average common shares outstanding: |
||||||||||||||||
| Basic |
14,273 | 14,578 | 14,339 | 14,721 | ||||||||||||
| Diluted |
14,669 | 14,578 | 14,339 | 14,721 | ||||||||||||
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
(unaudited)
| December 31, | December 31, | |||||||
| ASSETS | 2025 | 2024 | ||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 57,481 | $ | 55,629 | ||||
| Accounts receivable, net |
23,690 | 23,594 | ||||||
| Inventories, net |
18,787 | 23,809 | ||||||
| Prepaid expenses and other current assets |
3,400 | 5,494 | ||||||
| Current assets held for sale |
— | 5,126 | ||||||
|
|
|
|
|
|||||
| Total current assets |
103,358 | 113,652 | ||||||
| Property and equipment, net |
40,324 | 38,994 | ||||||
| Right-of-use assets |
25,939 | 25,685 | ||||||
| Other long-term assets |
4,034 | 5,656 | ||||||
| Notes receivable |
5,636 | 5,935 | ||||||
| Deferred tax assets |
1,275 | 1,177 | ||||||
| Intangible assets, net |
1,650 | 2,490 | ||||||
| Goodwill |
8,054 | 7,125 | ||||||
| Non-current assets held for sale |
— | 2,026 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 190,270 | $ | 202,740 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 6,041 | $ | 5,617 | ||||
| Accrued expenses and other current liabilities |
15,867 | 13,567 | ||||||
| Current liabilities held for sale |
— | 4,122 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
21,908 | 23,306 | ||||||
| Other long-term liabilities |
701 | 772 | ||||||
| Lease liabilities |
24,196 | 24,014 | ||||||
| Non-current liabilities held for sale |
— | 659 | ||||||
| Stockholders’ equity: |
||||||||
| Common stock, $0.01 par value |
139 | 144 | ||||||
| Additional paid-in-capital |
87,498 | 88,961 | ||||||
| Accumulated other comprehensive loss |
(4,959 | ) | (6,783 | ) | ||||
| Retained earnings |
60,787 | 71,667 | ||||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
143,465 | 153,989 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 190,270 | $ | 202,740 | ||||
|
|
|
|
|
|||||
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| For the Years Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: |
||||||||
| Net loss |
$ | (10,880 | ) | $ | (56,385 | ) | ||
| Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
| Depreciation |
5,372 | 6,884 | ||||||
| Amortization of acquisition related intangible assets |
357 | 1,237 | ||||||
| Non-cash operating lease cost |
2,061 | 2,150 | ||||||
| (Gain) loss on sale of assets |
(166 | ) | 2,864 | |||||
| Loss on impairment of intangible asset |
— | 2,462 | ||||||
| Stock-based compensation expense |
10,084 | 13,130 | ||||||
| Deferred income taxes |
(7 | ) | 260 | |||||
| Provision for doubtful accounts |
265 | 1,185 | ||||||
| Provision for inventory |
5,821 | 44,708 | ||||||
| Interest income on notes receivable |
(896 | ) | — | |||||
| Changes in operating assets and liabilities: |
||||||||
| Accounts receivable |
408 | 3,366 | ||||||
| Inventories |
30 | (9,424 | ) | |||||
| Prepaid expenses, other current and long-term assets |
2,327 | 558 | ||||||
| Accounts payable |
42 | (2,506 | ) | |||||
| Operating lease liabilities |
(1,996 | ) | (2,082 | ) | ||||
| Accrued expenses, other current and long-term liabilities |
(1,500 | ) | (3,669 | ) | ||||
| Income taxes |
(134 | ) | 665 | |||||
|
|
|
|
|
|||||
| Net cash provided by operating activities |
11,188 | 5,403 | ||||||
|
|
|
|
|
|||||
| Cash flows from investing activities: |
||||||||
| Purchases of property and equipment |
(6,826 | ) | (7,734 | ) | ||||
| Proceeds from sale of Parcus |
4,496 | — | ||||||
| Note receivable |
1,329 | — | ||||||
| Proceeds from sale of intangible asset |
600 | — | ||||||
| Acquisition of intangible asset |
— | (600 | ) | |||||
|
|
|
|
|
|||||
| Net cash used in investing activities |
(401 | ) | (8,334 | ) | ||||
|
|
|
|
|
|||||
| Cash flows from financing activities: |
||||||||
| Repurchases of common stock |
(9,485 | ) | (10,914 | ) | ||||
| Proceeds from employee stock purchase plan |
500 | 708 | ||||||
| Cash paid for tax withheld on vested restricted stock awards |
(1,566 | ) | (2,599 | ) | ||||
| Proceeds from exercises of equity awards |
— | 76 | ||||||
|
|
|
|
|
|||||
| Net cash used in financing activities |
(10,551 | ) | (12,729 | ) | ||||
|
|
|
|
|
|||||
| Exchange rate impact on cash |
86 | (48 | ) | |||||
|
|
|
|
|
|||||
| Increase (decrease) in cash and cash equivalents |
322 | (15,708 | ) | |||||
| Cash and cash equivalents at beginning of period |
57,159 | 72,867 | ||||||
|
|
|
|
|
|||||
| Cash and cash equivalents at end of period |
$ | 57,481 | $ | 57,159 | ||||
|
|
|
|
|
|||||
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Income (Loss) from Continued Operations to Adjusted EBITDA
(in thousands)
(unaudited)
| For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Income (loss) from continuing operations |
$ | 1,801 | $ | (2,486 | ) | $ | (9,979 | ) | $ | (8,828 | ) | |||||
| Interest and other (income) expense, net |
(118 | ) | (744 | ) | (1,744 | ) | (2,337 | ) | ||||||||
| Provision for income taxes |
(1,037 | ) | 2,524 | 672 | 6,064 | |||||||||||
| Depreciation and amortization |
1,318 | 1,434 | 5,580 | 5,688 | ||||||||||||
| Stock-based compensation |
2,458 | 2,251 | 10,216 | 12,158 | ||||||||||||
| Product rationalization |
— | 606 | — | 606 | ||||||||||||
| Non-recurring professional fees |
116 | — | 596 | — | ||||||||||||
| Costs of shareholder activism |
— | — | — | 2,185 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted EBITDA |
$ | 4,538 | $ | 3,585 | $ | 5,341 | $ | 15,536 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations
(in thousands)
(unaudited)
| For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Income (loss) from continuing operations |
$ | 1,801 | $ | (2,486 | ) | $ | (9,979 | ) | $ | (8,828 | ) | |||||
| Product rationalization, tax effected |
— | 457 | — | 457 | ||||||||||||
| Stock-based compensation, tax effected |
2,636 | 1,697 | 10,954 | 9,167 | ||||||||||||
| Non-recurring professional fees, tax effected |
124 | — | 639 | — | ||||||||||||
| Costs of shareholder activism, tax effected |
— | — | — | 1,647 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted net income (loss) from continuing operations |
$ | 4,561 | $ | (332 | ) | 1,614 | $ | 2,443 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Opertions Per Share
(in thousands, except per share data)
(unaudited)
| For the Three Months Ended December 31, | For the Years Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Diluted income (loss) from continuing operations per share |
$ | 0.12 | $ | (0.17 | ) | $ | (0.70 | ) | $ | (0.60 | ) | |||||
| Product rationalization, tax effected |
$ | — | 0.03 | $ | — | 0.03 | ||||||||||
| Stock-based compensation, tax effected |
$ | 0.18 | 0.11 | $ | 0.77 | 0.62 | ||||||||||
| Non-recurring professional fees, tax effected |
$ | 0.01 | — | $ | 0.04 | — | ||||||||||
| Costs of shareholder activism, tax effected |
$ | — | — | — | 0.11 | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted diluted net income (loss) from continuing operations per share |
$ | 0.31 | $ | (0.03 | ) | $ | 0.11 | $ | 0.16 | |||||||
|
|
|
|
|
|
|
|
|
|||||||||
Anika Therapeutics, Inc. and Subsidiaries
Revenue by Product Family
(in thousands, except percentages)
(unaudited)
| For the Three Months Ended December 31, | For the Year Ended December 31, | |||||||||||||||||||||||||||||||
| 2025 | 2024 | $ change | % change | 2025 | 2024 | $ change | % change | |||||||||||||||||||||||||
| OEM Channel |
$ | 17,313 | $ | 19,669 | $ | (2,356 | ) | -12 | % | $ | 64,406 | $ | 77,770 | $ | (13,364 | ) | -17 | % | ||||||||||||||
| Commercial Channel |
13,302 | 10,933 | 2,369 | 22 | % | 48,413 | 42,137 | 6,276 | 15 | % | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| $ | 30,615 | $ | 30,602 | $ | 13 | 0 | % | $ | 112,819 | $ | 119,907 | $ | (7,088 | ) | -6 | % | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
FAQ
How did Anika Therapeutics (ANIK) perform financially in Q4 2025?
What were Anika Therapeutics (ANIK) full-year 2025 revenue and profit metrics?
How strong was Anika Therapeutics (ANIK) cash flow and balance sheet in 2025?
What is happening with Anika Therapeutics (ANIK) Executive Vice President and General Counsel David Colleran?
What progress did Anika Therapeutics (ANIK) report on Hyalofast and Cingal?
What is Anika Therapeutics (ANIK) doing with its share repurchase program?
How did Anika Therapeutics (ANIK) Commercial and OEM channels perform in 2025?
Filing Exhibits & Attachments
5 documentsPress Releases
Agreements & Contracts
